R Squared Ltd Purchases 37,859 Shares of Kenvue Inc. $KVUE

R Squared Ltd increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 136.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,589 shares of the company’s stock after buying an additional 37,859 shares during the quarter. Kenvue accounts for about 0.6% of R Squared Ltd’s portfolio, making the stock its 21st biggest holding. R Squared Ltd’s holdings in Kenvue were worth $1,131,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of KVUE. Vanguard Group Inc. grew its stake in shares of Kenvue by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after acquiring an additional 1,604,040 shares in the last quarter. State Street Corp lifted its position in shares of Kenvue by 3.5% in the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after purchasing an additional 4,063,257 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Kenvue by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after purchasing an additional 371,322 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after purchasing an additional 17,343,785 shares during the last quarter. Finally, Norges Bank bought a new position in Kenvue in the fourth quarter valued at $756,862,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE traded up $0.35 during mid-day trading on Tuesday, hitting $19.91. The stock had a trading volume of 4,881,569 shares, compared to its average volume of 30,253,311. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The company’s 50 day simple moving average is $17.90 and its 200 day simple moving average is $17.73. The stock has a market cap of $38.24 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 1.50 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 EPS. On average, equities research analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.2%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is currently 97.65%.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.59% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. UBS Group reduced their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Citigroup decreased their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Barclays lowered their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Finally, Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.